Rozlytrek

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Non-small cell lung cancer with ROS proto-oncogene 1Pediatric Solid tumors and primary central nervous system (CNS) tumorsSolid tumorsThis is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study)and do not have access to the treatment locallyreceptor tyrosine kinase (ROS1) gene rearrangements

Phase 1

A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX -101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or who have no Satisfactory Treatment Options

Active, not recruitingCTIS2023-505088-35-00

F. Hoffmann-La Roche AGPediatric Solid tumors and primary central nervous system (CNS) tumors

Start: 2019-12-12Target: 25Updated: 2025-07-21

Phase 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruitingCTIS2023-507418-28-00

F. Hoffmann-La Roche AGSolid tumors

Start: 2021-03-15Target: 407Updated: 2025-12-09

Phase 3

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

RecruitingCTIS2023-504263-16-00

F. Hoffmann-La Roche AGand do not have access to the treatment locally, This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study)

Start: 2023-05-25Target: 21Updated: 2025-11-05

Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements with and Without Central Nervous System Metastases

RecruitingCTIS2023-507494-18-00

F. Hoffmann-La Roche AGNon-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

Start: 2021-09-24Target: 91Updated: 2026-01-20